Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome

por Jung, Hyun Ae, Jung, Chul Won, Jang, Jun Ho
Publicado 2021

Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience

por Jung, Hyun Ae, Jang, Mi-Ae, Kim, Kihyun, Kim, Sun-Hee
Publicado 2018

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients

por Jung, Hyun Ae, Maeng, Chi Hoon, Kim, Moonjin, Kim, Sungmin, Jung, Chul Won, Jang, Jun Ho
Publicado 2015

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer

por Jung, Hyun Ae, Park, Sehhoon, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Sun, Jong-Mu
Publicado 2023

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer

por Park, Sehhoon, Jung, Hyun Ae, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Sun, Jong-Mu
Publicado 2023

Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

por Hur, Joon Young, Ku, Bo Mi, Park, Sehhoon, Jung, Hyun Ae, Lee, Se-Hoon, Ahn, Myung-Ju
Publicado 2022

EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis

por Kim, Hongsik, Park, Sehhoon, Jung, Hyun Ae, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju
Publicado 2023

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea

por Lee, Kangkook, Jung, Hyun Ae, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Publicado 2020

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

por Jung, Hyun Ae, Park, Sehhoon, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil
Publicado 2020

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors

por Kim, Hongsik, Jung, Hyun Ae, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Sun, Jong-Mu
Publicado 2021

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

por Kim, Hana, Park, Sehhoon, Jung, Hyun Ae, Lee, Se-Hoon, Park, Keunchil, Ahn, Yong Chan, Oh, Dongryul, Ahn, Myung-Ju
Publicado 2023

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

por Kim, Hyera, Kwon, Minsuk, Kim, Binnari, Jung, Hyun Ae, Sun, Jong-Mu, Lee, Se-Hoon, Park, Keunchil, Ahn, Myung-Ju
Publicado 2020

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

por Jung, Hyun Ae, Woo, Sook Young, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Sun, Jong-Mu
Publicado 2020

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled...

por Jung, Hyun Ae, Park, Sehhoon, Choi, Yoon-La, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Sun, Jong-Mu
Publicado 2022

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

por Choi, Seung Won, Jung, Hyun Ae, Cho, Hee‐Jin, Kim, Tae Min, Park, Chul‐Kee, Nam, Do‐Hyun, Lee, Se‐Hoon
Publicado 2023

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

por Jeon, Youngkyung, Jung, Hyun Ae, Park, Sehhoon, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Lee, Se-Hoon
Publicado 2023

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

por Jun, Soojin, Park, Sehhoon, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Cho, Juhee, Jung, Hyun Ae
Publicado 2023

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment

por Kim, Hongsik, Park, Sehhoon, Jung, Hyun Ae, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Publicado 2022

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

por Byeon, Seonggyu, Cho, Jang Ho, Jung, Hyun Ae, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung‐Ju
Publicado 2020

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

por Park, Sehhoon, Ku, Bo Mi, Jung, Hyun Ae, Sun, Jong-Mu, Ahn, Jin Seok, Lee, Se-Hoon, Park, Keunchil, Ahn, Myung-Ju
Publicado 2020